Piper Jaffray Transitions Rating on AtriCure (ATRC) to Underweight; Risk/Reward Less Attractive
ATRC Hot Sheet
Rating Summary:5 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Piper Jaffray & Co. transitions rating on AtriCure (Nasdaq: ATRC) to Underweight.
Piper analyst says, "We now rate AtriCure Underweight given that its risk/reward profile appears less attractive than its peers. Relative to our target price of $4.00, the stock still offers 10%+ potential appreciation. However, with the risk associated with the ongoing Department of Justice investigation, we'd like to see a greater reward potential...With the stock valued at roughly 1x our C10 revenue estimate, it trades at a discount to other small cap cardiology companies. Under normal circumstances, we'd argue that companies competing in the AF space could trade at a premium to the group given the growth prospects in the space. But in this instance, we think a discount is warranted given the uncertainty tied to the ongoing DOJ investigation...DOJ Investigation Continues To Be An Overhang."
To see more analyst ratings on ATRC Click Here.
AtriCure, Inc. is a medical device company that develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.
Piper analyst says, "We now rate AtriCure Underweight given that its risk/reward profile appears less attractive than its peers. Relative to our target price of $4.00, the stock still offers 10%+ potential appreciation. However, with the risk associated with the ongoing Department of Justice investigation, we'd like to see a greater reward potential...With the stock valued at roughly 1x our C10 revenue estimate, it trades at a discount to other small cap cardiology companies. Under normal circumstances, we'd argue that companies competing in the AF space could trade at a premium to the group given the growth prospects in the space. But in this instance, we think a discount is warranted given the uncertainty tied to the ongoing DOJ investigation...DOJ Investigation Continues To Be An Overhang."
To see more analyst ratings on ATRC Click Here.
AtriCure, Inc. is a medical device company that develops, manufactures and sells cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Barclays Lowers PT and Estimates on Royal Bank of Canada (RY); Coming Off The Bandwagon
- Brean Murray Carret & Co. Downgrades NetApp (NTAP) to Hold; Visibility Challenged
Create E-mail Alert Related Categories
Downgrades, New CoverageRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
